Company intelligence / Profile preview
Pharmathen
Pallini, Greecepharmathen.com ↗
- Ownership
- Private
- Employees
- ~1700
- Development stage
- Other
01
Overview
Pharmathen has over 90 commercialized products sold to 250 customers in more than 90 countries. The company has received FDA approvals for multiple products including the first generic microsphere LAIs (naltrexone, risperidone, octreotide)[3][8].
- Therapeutic areas
- PsychiatryUrologyOphthalmologyEndocrinologyNeurology
- Modalities
- Long-Acting Injectables (LAI)Sustained Release Oral Solid formulationsOphthalmic formulationsPreservative-free formulations
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Network of 250+ customers in 90+ countries[1][9]
Beyond the preview
Go deeper on Pharmathen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pharmathen.